Dementia 'chemical cosh' warnings

Experts have found more evidence that prescribing dementia patients "chemical cosh" drugs increases their risk of early death.

Antipsychotics are widely used in care homes and hospitals, but critics argue they are often given to sedate patients to make them easier to look after rather than for any medical benefit.

Guidelines say they should only be used as a last resort and over a short period of time, but in some cases patients have been prescribed them for years.

The latest research from Harvard Medical School is the biggest ever among US nursing home residents, involving 75,445 people aged 65 and over.

It examined a range of drugs and found one in particular - haloperidol -increased the risk a patient would die. Haloperidol is widely used in the UK as well as the US. Compared with the drug risperidone, users of haloperidol had double the risk of death, while those on another drug, quetiapine, had a decreased risk, the study found.

Writing online in the British Medical Journal, the experts concluded: "The data suggest that the risk of mortality with these drugs is generally increased with higher doses and seems to be highest for haloperidol and least for quetiapine." They suggest not all antipsychotic medication carries the same risk of death but that doctors may want to consider the evidence when prescribing the drugs.

Previous studies have found that antipsychotics as a class of drugs double the risk of death and treble the risk of stroke in dementia patients.

A Government-commissioned review in 2009 found 180,000 people with dementia were prescribed antipsychotics, of which 144,000 were given them inappropriately.

The drugs have been dubbed a "chemical cosh" due their effects and are thought to contribute to the premature deaths of 1,800 patients a year.

Rebecca Wood, chief executive at Alzheimer's Research UK, said: "The risks associated with antipsychotics are well-established, and these findings underline the importance of ensuring that where these drugs are prescribed, their use must be carefully monitored."

Go here to see the original:
Dementia 'chemical cosh' warnings

Dementia ‘chemical cosh’ warnings

Experts have found more evidence that prescribing dementia patients "chemical cosh" drugs increases their risk of early death.

Antipsychotics are widely used in care homes and hospitals, but critics argue they are often given to sedate patients to make them easier to look after rather than for any medical benefit.

Guidelines say they should only be used as a last resort and over a short period of time, but in some cases patients have been prescribed them for years.

The latest research from Harvard Medical School is the biggest ever among US nursing home residents, involving 75,445 people aged 65 and over.

It examined a range of drugs and found one in particular - haloperidol -increased the risk a patient would die. Haloperidol is widely used in the UK as well as the US. Compared with the drug risperidone, users of haloperidol had double the risk of death, while those on another drug, quetiapine, had a decreased risk, the study found.

Writing online in the British Medical Journal, the experts concluded: "The data suggest that the risk of mortality with these drugs is generally increased with higher doses and seems to be highest for haloperidol and least for quetiapine." They suggest not all antipsychotic medication carries the same risk of death but that doctors may want to consider the evidence when prescribing the drugs.

Previous studies have found that antipsychotics as a class of drugs double the risk of death and treble the risk of stroke in dementia patients.

A Government-commissioned review in 2009 found 180,000 people with dementia were prescribed antipsychotics, of which 144,000 were given them inappropriately.

The drugs have been dubbed a "chemical cosh" due their effects and are thought to contribute to the premature deaths of 1,800 patients a year.

Rebecca Wood, chief executive at Alzheimer's Research UK, said: "The risks associated with antipsychotics are well-established, and these findings underline the importance of ensuring that where these drugs are prescribed, their use must be carefully monitored."

Go here to see the original:
Dementia 'chemical cosh' warnings

Dementia: Some Antipsychotic Drugs Riskier Than Others

Among Drugs Used to Calm Agitated Dementia Patients, Newer Drugs Seem Safer Than Older

Feb. 23, 2012 -- The FDA has warned that treatment with antipsychotic drugs increases the risk of death among elderly patients with dementia, and now a new study confirms that some drugs are riskier than others.

Compared to patients treated with the newer second-generation antipsychotic drug Risperdal (risperidone), patients who took the older, first-generation drug Haldol (haloperidol) had twice the risk of death.

The study is by far the largest ever to examine death risk associated with antipsychotic drug use in patients with dementia. The drugs are often used to calm down dementia patients who can become agitated, sometimes to the point of violence.

Researchers from Harvard Medical School reviewed data on more than 75,400 elderly residents of nursing homes in 45 states across the U.S.

They conclude that certain antipsychotic medications may differ in the risk of death among the elderly with dementia.

The study appears today in the journal BMJ.

“Haloperidol is not used as much as it once was in these patients, but it is still used,” says researcher and Harvard Medical School instructor Krista Huybrechts, PhD. “It is clear that this drug carries an increased risk for death in elderly patients with dementia and should not be used.”

FDA Warning Prompted Study

In 2005, the FDA warned that second-generation antipsychotic drugs, also known as atypical antipsychotics, were associated with an increased risk of death in older patients with Alzheimer’s disease and other age-related dementias.

In 2008, the warning was expanded to include conventional, first-generation antipsychotic drugs.

Despite the safety concerns, both first- and second-generation antipsychotics are still prescribed for the treatment of agitated elderly dementia patients when non-medical interventions have failed, geriatrician Gisele Wolf-Klein, MD, tells WebMD.

Wolf-Klein is director of geriatric education at the North Shore-LIJ Health System in New Hyde Park, N.Y.

“There is a perception that nursing homes are putting patients on these drugs to keep them quiet, but that isn’t the case,” she says. “When we prescribe these medications it is usually as a last resort.”

Death Risk Lowest in Seroquel Users

The Harvard Study included elderly new users of antipsychotic drugs residing in nursing homes across the U.S. between 2001 and 2005. The antipsychotics evaluated in the study were Abilify, Geodon, Haldol, Risperdal, Seroquel, and Zyprexa.

Among the major findings:

Compared to Risperdal users, Haldol users were twice as likely to die from non-cancer-related causes during a six-month observation period, with the largest number of deaths occurring during the first 40 days of treatment. Users of the second-generation drug Seroquel (quetiapine) had a slightly lower risk for death than users of Risperdal. The death rate among users of Abilify (aripiprazole), Zyprexa (olanzapine), and Geodon (ziprasidone) was similar to that of patients who took Risperdal.

The study is the first to suggest that Seroquel carries a lower risk for death than other second-generation antipsychotic drugs, and Huybrechts says more study is needed to confirm the finding.

See original here:
Dementia: Some Antipsychotic Drugs Riskier Than Others

More on movement disorders

THE Malaysian National Movement Disorders Society, Lloyd Tan Parkinson?s Trust Fund and the Negri Sembilan Parkinson?s Society will hold the inaugural ?Cultivate Hope? event from March 2 to 4 at 1Utama shopping centre in Petaling Jaya to raise awareness on Parkinson?s Disease (PD).

The highlight of this event is the launch of Red Tulip ? the official symbol of World Parkinson?s Day ? in Malaysia.

There will be general health screening, free Parkinson?s screening, information on movement disorders (MDs) and their latest treatments.

On March 4, patients are invited to attend a seminar titled Living a Meaningful Life after Parkinson?s delivered by Dr. Chew Nee Kong, and also participate in folding origami tulips as part of a fundraiser.

MDs are abnormal body movements caused by brain disorders such as ataxia, dystonia, Parkinson?s disease and tremor.

MDs are a significant national health burden in Malaysia, as there are 100,000 to 150,000 sufferers ? both young and the elderly.

As there are no cure for MDs, the progressive disease results in life-long physical and mental disabilities.

PD is a chronic, progressive disorder of the nervous system, which causes increasing and devastating disability over time.

It is estimated that there are 50,000 to 60,000 patients in Malaysia.

Health director-general Datuk Seri Dr Hasan Abdul Rahman will be launching the event and the unveiling of the Red Tulip.

For details and registration, contact Habsah (019-335 8872) or Joseph (016-648 4718) or visit http://www.facebook.com/mnmds or http://www.parkinsoninfo.my

See original here:
More on movement disorders

My point still stands: autism can take a flying leap

My point still stands: autism can take a flying leap February 23rd, 2012, 4:12 pm · · posted by Jo Ashline, OC Moms

This morning I published a blog post about autism here on the Mom Blog (which is part of the Orange County Register). It was taken down an hour later. The reason was NOT because it was, as one Facebook commenter put it,  “bigoted and offensive.” It was because I used a word that I learned the hard way can’t be used in a media outlet like OC Register.

And I respect that. I respect my editor. I respect the editors she answers to.

I respect that there are certain protocols in place that prevent me from being a potty mouth. Guidelines are in place for a reason and if I want to continue writing this blog, I’m going to have to find a more creative way to express my emotions than resorting to those tried and true no-no words.

I’m up to the challenge. I DO want to keep writing here. I have plenty more to say and plenty of people I haven’t offended yet.

But today I had to make a choice. As a writer I am faced with this inner voice that tells me whether or not something I put out is done so with integrity. That doesn’t mean that everything I write is award-winning or will move mountains, but it does mean that when I hit publish, I do so with the confidence that I’ve given it my all. Even if it’s a piece about Victoria Beckham.

I reread that post half a dozen times. I tried my best to think of replacements that would still get my point across. But darn it all to heck if I just didn’t get the same feeling when I filled in the blanks with, I Told Autism To Take A Flying Leap or  I Told Autism It Can See Itself Out or I Told Autism That Maybe It Can Sort Of Possibly Retreat But Only If It Feels Like It.

So I chose to leave it alone and post it on my personal website, joashline.com, where you can read it in its uncensored entirety. 

Now. To address these accusations of bigotry and hatred.

I do not speak from a place of discrimination. I do not speak from a place that puts some people before others. I have more diagnoses than I know what to do with, including but not limited to panic attack disorder, obsessive compulsive disorder, alcoholism and depression — and that’s just the first line of my medical file. These are all things that make up who I am, in part, but they are not things that I celebrate.

These are all diagnoses that have shaped me in some form or another, but I have no problem flipping them off after a bad day because of them, or after a particularly good one in spite of them.

The same is for my son’s autism. I do not consider him defined by his autism. I consider him affected and afflicted and hindered by it. That is our version. That is our reality. This is a child who requires 24 hours of non-stop supervision, because he would not think twice about running out into traffic or drinking bleach or walking off with a stranger or jumping into a body of water even though he cannot swim.

This is what our version of autism looks like.

We invest in doctors and therapy and innovative technology — not because maybe we think autism is kind of OK as long as we have a handle on it, but because we want to get rid of it. Because we see what it does to our loved ones and we hold onto the belief that it CAN and it WILL get better.

So my opinion stands. Autism can, er, take a flying leap.

And I promise to keep it legit on this site and entertain and anger and otherwise annoy you without the use of banned words. I used to teach kindergarten for goodness sake. I CAN do this!

But if you’re ever in the mood to hear a naughty word or two — because sometimes it’s that one naughty word that can really drive home a point — well then, you know where to find me.

 

Go here to see the original:
My point still stands: autism can take a flying leap

Larger brains for some boys with autism?

(SACRAMENTO, Calif.) -- In the largest study of brain development in preschoolers with autism to date, a study by UC Davis MIND Institute researchers has found that 3-year-old boys with regressive autism, but not early onset autism, have larger brains than their healthy counterparts.

The study is published online today in the Proceedings of the National Academy of Sciences Early Edition.  It was led by Christine Wu Nordahl, a researcher at the UC Davis MIND Institute and an assistant professor in the Department of Psychiatry and Behavioral Sciences and David G. Amaral, Beneto Foundation Chair, MIND Institute Research Director and University of California Distinguished Professor in the Department of Psychiatry and Behavioral Sciences.

"The finding that boys with regressive autism show a different form of neuropathology than boys with early onset autism is novel," Nordahl said. "Moreover, when we evaluated girls with autism separately from boys, we found that no girls - regardless of whether they had early onset or regressive autism -had abnormal brain growth."

Brain enlargement has been observed in previous studies of autism. However, prior to this study, little was known about how many and which children with autism have abnormally large brains.

"This adds to the growing evidence that there are multiple biological subtypes of autism, with different neurobiological underpinnings," Amaral said.

Autism is a neurodevelopmental disorder whose symptoms include deficits in language and social interaction and communication. The condition affects 1 in 110 children born today, according to the U.S. Centers for Disease Control and Prevention. It is diagnosed more frequently in male children than female children - at a ratio of 4 to 1.

The current study is one of the first published from data collected by the UC Davis MIND Institute Autism Phenome Project (APP). The project's goal is to recruit and enroll as many very young children as possible in order to collect sufficient biological and behavioral information to characterize different autism subgroups and to explore different neural, immunologic, and genetic signatures of autism.

For the study, the authors enrolled a total of 180 children between age 2 and 4. One hundred and fourteen of the participants had autism spectrum disorder; the remaining participants were 66 age-matched typically developing controls. Of the children with autism, 54 percent were diagnosed with the regressive form and 46 with the non-regressive type.

The researchers collected magnetic resonance imaging (MRI) scans on 180 participants at age 3. To evaluate the rate of brain growth prior to age 3, they analyzed head circumference measurements taken from pediatric well-baby visits from birth through 18 months. Roughly half of the children with autism were reported by their parents as having experienced a regression, characterized by the loss of previously acquired language and social skills.

MRIs were carried out on study participants during natural, nighttime sleep using protocols developed specifically for the Autism Phenome Project by Nordahl.

"Obtaining MRI scans in 3-year-old children without the use of sedation may seem quite challenging. But, by working closely with the parents, we actually were successful more than 85 percent of the time. Patience on the part of everyone and the dedication of the families was critical for our success," Nordahl said.

The study found that accelerated head growth and brain enlargement was consistently observed only in the subset of children diagnosed with regressive autism. Specifically, total brain volume in 3-year-old males with regressive autism was more than 6 percent larger than that of age-matched typically developing peers. Twenty-two percent of boys with regressive autism, as opposed to 5 percent of boys without regressive autism, had enlarged brains, the study found.

Changes in brain size were not apparent in boys who did not experience a regression. Girls with autism, regardless of autism onset status, also did not show abnormal brain growth. The study findings suggest that abnormalities in overall brain growth are specific to male children with the regressive type of autism, and that rapid brain growth may be a risk factor for regression, the researchers said.
   
While brain size was clearly larger at age 3, the study also determined when the precocious growth began, by examining records of head circumference that provides a reasonable estimate of brain size in young children. These analyses clearly indicated that brain growth diverged from normal at around 4 to 6 months of age. This is of particular interest, because many families believe that the trigger that led to their child's regression took place close to the time that the regression happened. But the data reported in this paper indicate that the process leading to the enlarged brain, which presumably also is associated with the onset of autism, started when the child was a newborn.

Much remains to be elucidated regarding brain changes associated with autism, the authors note. In the current study, not all boys with regression demonstrate the precocious brain growth. The investigative team also continues efforts to define the underlying brain pathology in children with early onset autism and in girls with autism. 
    
"It is not clear how many different types of autism will be identified," Amaral said. "The purpose of defining different types of autism is to more effectively study the cause of each type and eventually determine effective preventative measures and better, individualized treatments. This is a first step in defining autism subtypes based on the data from the Autism Phenome Project, but it certainly will not be the last. There are already indications that other subtypes of autism will be more closely associated with immunological differences or genetic alterations."

The study's other authors are Nicholas Lange of the Department of Psychiatry and Biostatistics at Harvard University Schools of Medicine and Public Health McLean Hospital; Deana D. Li, Lou Ann Barnett, Aaron Lee, Tony J. Simon, Sally Rogers and Sally Ozonoff of the UC Davis MIND Institute and the Department of Psychiatry and Behavioral Sciences in the UC Davis School of Medicine; and Michael H. Buonocore of the Department of Radiology, UC Davis School of Medicine.

The study was funded by grants from the National Institute of Mental Health and the University of California, Davis Medical Investigation of Neurodevelopmental Disorders (MIND) Institute.

At the UC Davis MIND Institute, world-renowned scientists engage in research to find improved treatments as well as the causes and cures for autism, attention-deficit hyperactivity disorder, fragile X syndrome, Tourette syndrome and other neurodevelopmental disorders. Advances in neuroscience, molecular biology, genetics, pharmacology and behavioral sciences are making inroads into a better understanding of brain function. The UC Davis MIND Institute draws from these and other disciplines to conduct collaborative, multidisciplinary research. For more information, visit http://mindinstitute.ucdavis.edu.

Read more:
Larger brains for some boys with autism?

Low birth weight may increase autism risk, study finds

Low birth weight affects a child's risk of having an autism spectrum disorder (ASD), according to a study conducted by a Northwestern University researcher.

After studying 3,715 pairs of twins that include one twin with an ASD, Northwestern researcher Molly Losh learned that a weight difference of at least 15 percent or 400 grams made the smaller twin three times more likely to have an ASD.

Losh directs Northwestern's Neurodevelopmental Disabilities Laboratory and teaches at Northwestern's School of Communication.

The twins were born between 1992 and 1995 and are part of the Swedish Twin Registry's Child and Adolescent Twin Study, which is directed by Paul Lichtenstein at Sweden's Karolinska Institute. The twins in Losh's study were the same sex, but included both identical and fraternal pairs.

"This is the first study of its size that links low birth weight with the potential for autism," said Losh. "Looking at twins is a good way to study autism because the unaffected twins serve as the controls."

The causes of autism are complex, but this study gives scientists one more clue, said Losh. "We already knew the genetic link, that you are more likely to have autism if you have a family history of it or have relatives that family members described as 'anti-social' and 'aloof.' This study helps us narrow down the environmental factors. But there are still a lot of unknowns."

ASD is an umbrella term that includes developmental disabilities that can cause "significant social, communication and behavioral challenges," according to the Centers for Disease Control and Prevention. Lack of social interaction is the common thread, although severity ranges from mild to severe.

The syndrome is an equal-opportunity condition, crossing racial, ethnic and socioeconomic lines. Its various forms are four times more common among boys than girls. They affect 1 in 110 children, the CDC said.

Children diagnosed with an ASD are more common today, but the CDC said scientists are not sure if that is due to better diagnoses or an increased rate of the disorders.

Years ago, said Losh, parents were blamed for autism. "Mothers were called 'refrigerator moms' because they were accused of being cold with their babies," she said. "In fact, I see just the opposite. These parents are doing all they can to help these children."

Losh's study will be published in a spring 2012 issue of the journal Psychological Medicine.

The rest is here:
Low birth weight may increase autism risk, study finds

Meds for Autism Not Well Understood: Study

THURSDAY, Feb. 23 (HealthDay News) -- Children with autism may benefit from medications to treat children with attention-deficit hyperactivity disorder (ADHD) and other related disorders, but clearer guidelines are needed, a new study shows.

Researchers analyzed data from more than 1,000 U.S. teens enrolled in special education programs, to assess the use of psychiatric medications in those with autism, ADHD and both conditions.

Patients with both autism and ADHD had the highest rates of medicine use (about 58 percent), followed by those with ADHD only (around 49 percent) and those with autism only (about 34 percent), according to study author Paul Shattuck, an assistant professor at Washington University in St. Louis, and colleagues.

Black teenagers with autism only or with autism and ADHD were less likely to receive medications than whites.

"Observations from the present study reinforce the complexity of pharmacologic treatment of challenging behavior in kids with [autism spectrum disorders] and ADHD," Shattuck said in a university news release. "There needs to be a clearer guide for treating kids with both an [autism spectrum disorder] and ADHD."

He noted that drug treatment for autism reflects a trial-and-error approach based on associated symptoms, and there is a poor understanding of overall medication use for children with autism.

"Also striking are the high rates of antipsychotic, antidepressant/anti-anxiety and stimulant medication use in these youths," Shattuck said. "Additional studies examining the treatment of core and associated [autism spectrum disorder] symptoms are needed to guide the treatment of these kids."

It is estimated that one in 110 people have autism, with the majority being boys. Signs of autism include problems with communication and social interactions.

The study appears in the Journal of Child and Adolescent Psychopharmacology.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more about autism.

Originally posted here:
Meds for Autism Not Well Understood: Study

Stem Cell Clinical Trial for Heart Failure: Eduardo Marban – CIRM Spotlight on Disease – Video

21-12-2011 10:03 CIRM has funded a $5.5 million Disease Team to develop a follow on clinical trial that uses a patient's own heart stem cells to regenerate scarred tissue damaged by a heart attack. The team is led by Eduardo Marban, MD, PhD, Director of the Cedars-Sinai Heart Institute. Marban presented the team's latest progress at the December 8th, 2011 CIRM Governing Board meeting. Fred Lesikar, a participant in a current trial, also spoke to Board and described the dramatic improvement he's experienced since receiving his heart stem cells two years ago. The speakers were introduced by Shlomo Melmed, MD, and Jonathan Thomas, PhD, JD. Melmed is a CIRM Governing Board member and Senior Vice-President for Academic Affairs and Dean of the Medical Faculty at Cedars-Sinai. Thomas is Chair of the CIRM Governing Board.

Read more from the original source:
Stem Cell Clinical Trial for Heart Failure: Eduardo Marban - CIRM Spotlight on Disease - Video

Surgeons Urge Caution: Stem Cell Treatments Untested in Aesthetic Surgery

Doctors Haeck, Eaves, and Rohrich write joint ASAPS/ASPS statement calling for more research into stem cell facelift and stem cell breast augmentation.

Dallas, TX (PRWEB) February 22, 2012

There is little evidence to support the safety and effectiveness of procedures, equipment and treatments that have been advertised using adult stem cells for aesthetic reconstruction, including plastic surgery and facial rejuvenation, according to physicians writing in Plastic and Reconstructive Surgery.

Dr. Rod J. Rohrich, chairman of the Department of Plastic Surgery at UT Southwestern Medical Center and editor-in-chief of the journal, published a position statement on “stem cell facelifts” and “stem cell breast augmentation,” also known as “natural breast augmentation.” Dr. Felmont F. Eaves III of Chapel Hill, N.C., and Dr. Phillip C. Haeck of Seattle, Wash.,collaborated on the statement on behalf of the American Society for Aesthetic Plastic Surgery (ASAPS) and the American Society of Plastic Surgeons (ASPS).

“There are encouraging data from studies in laboratories to suggest that the use of adult stem cells is a very promising field and may produce beneficial medical therapies to treat a variety of diseases,” the doctors said in the statement. They emphasized that there is a lack of consistency in the way stem cell facelift procedures are performed, and pointed out that many procedures are being advertised by physicians who are not board-certified for this type of treatment, and devices being sold for aesthetic stem cell treatments have not been approved for human use in the U.S.

In the report, the doctors encourage their peers to continue reporting clinic results and experimental research to peer-reviewed plastic surgery journals to both promote good science and to foster safety and best practices for stem cell use in aesthetic procedures. “Much more research needs to be conducted before any definitive statements can be made,” the report said. “[Until then,] stem cell based procedures should be performed in compliance with FDA regulatory guidelines.”

Dr. Rohrich said many of the advertisements claiming stem cells can aid in restoring facial and body youthfulness come from outside the U.S. “Further direct, approved clinical research is needed to validate those claims,” he said, “but the future is potentially bright for the use of adult stem cells in both plastic surgery and facial rejuvenation, as well as in medical procedures, such as restoring nerve and brain damage resulting from trauma or cancer, as well as reversing the severe effects of auto immune disease.”

To read the complete joint ASAPS/ASPS position statement on stem cell use in aesthetic surgery, including stem cell facelifts and natural breast augmentation, visit the ASPS, at their website.

About Rod J. Rohrich, M.D., F.A.C.S.
Dr. Rod J. Rohrich holds the Betty and Warren Woodward Chair in Plastic and Reconstructive Surgery at UT Southwestern Medical Center in Dallas, Texas. He also holds the UT Southwestern Medical Center Crystal Charity Ball Distinguished Chair in Plastic Surgery. He is a graduate of the Baylor College of Medicine with high honors, with residencies at the University of Michigan Medical Center and fellowships at the Massachusetts General Hospital/Harvard (hand/microsurgery) and Oxford University (pediatric plastic surgery). He has served as president of the American Society of Plastic Surgeons. He repeatedly has been selected by his peers as one of America's best doctors, and twice has received one of his profession's highest honors, the Plastic Surgery Educational Foundation Distinguished Service Award, which recognizes his contributions to education in his field. Dr. Rohrich participates in and has led numerous associations and councils for the advancement of plastic and reconstructive surgery. He is a native of North Dakota. He is married to Dr. Diane Gibby, also a plastic surgeon. They live in Texas with their two children.

###

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebplastic-surgery/stem-cell-statement/prweb9217080.htm

Original post:
Surgeons Urge Caution: Stem Cell Treatments Untested in Aesthetic Surgery

Stem Cell Action Coalition Opposes Virginia Personhood Bill

To: HEALTH, MEDICAL AND POLITICAL EDITORS

WASHINGTON, Feb. 23, 2012 /PRNewswire-USNewswire/ -- The Stem Cell Action Coalition opposes Virginia House Bill No.1, the so-called Virginia "personhood bill." The Virginia Senate Committee on Education and Health is scheduled to take the matter up this week.

The language of the personhood bill states, in part, that the laws of Virginia "shall be interpreted and construed to acknowledge on behalf of unborn children at every stage of development all of the rights, privileges and immunities available to other persons, citizens and residents." The bill further states "unborn children shall include the offspring of human beings from the moment of conception until birth at every stage of biological development."

HB 1 arguably would apply to every aspect of Virginia law thus profoundly impacting inheritance, adoption, guardianship, civil and criminal liability by according the same rights as adults and children to a single cell.

The personhood bill would surely interfere with reproductive and related rights of women and couples along several fronts. These interferences include making it exceedingly difficult for couples in Virginia to seek in vitro fertilization as a means of creating families and donating for research IVF-created embryos not needed for implantation or not sufficiently healthy for implantation. Moreover, the law would prevent the pursuit of medical research in Virginia that utilizes human embryonic stem cells.

In this twisted new world, Virginia researchers deriving embryonic stem cells from donated embryos might be charged with capital crimes, even murder. Couples donating embryos to research might be designated as accessories to these crimes. Microscopic embryos, consisting of a few cells in lab dishes or frozen in IVF clinics might be designated as wards of the state and by mandate have legal guardians appointed on their behalf.

Human embryonic stem cell research has been described by scientists as the "gold standard" for those seeking to develop cures based on stem cell technology for many diseases and maladies such as Parkinson's, ALS, diabetes, MS, macular degeneration and other causes of blindness, spinal cord injuries, and other medical conditions for which there is no known cure.

Bernard Siegel, J.D., spokesperson for the Coalition and executive director of the Genetics Policy Institute commented, "It is a sad day indeed when the Commonwealth of Virginia should become an outpost for extremism by impeding potentially lifesaving scientific research. Thomas Jefferson would be appalled. The wise voters of Colorado (twice) and Mississippi overwhelmingly rejected personhood amendments to their state constitutions.

The profound implications of the personhood bill cannot be wished away by its sponsors. Passage of this bill would be an affront to couples trying to avail themselves of modern infertility treatments, stem cell researchers targeting cures and to all Virginians suffering from chronic and life threatening disease. Passage of HB 1 is akin to crushing hope.

Human embryonic stem cell research holds the promise of discovering the root causes of disease, serves as a tool for drug discovery, and will surely lead to regenerative medicines and cell therapies for repairing or replacing damaged tissues and organs.

Microscopic cells in a lab dish, that by a couples' decision, will never be implanted in a womb, should not be defined as 'people'," Siegel continued.

HB 1 represents a concerted move by opponents of all forms of early termination of pregnancy and medical research involving human embryos to attempt to pass laws to define "person" as the being that comes into existence at conception. In addition to Virginia, similar efforts to pass "personhood" legislation are underway in Oklahoma, Mississippi and in other states.

The Stem Cell Action Coalition has 75 nonprofit affiliated organizations including patient groups, medical philanthropies, scientific and medical societies and public interest organizations all dedicated to advancing scientifically meritorious and ethically responsible research.

The Stem Cell Action Coalition serves as an engine to unite the pro-cures community. It recognizes that human embryonic stem cell research must be a national public health priority at all branches and levels of government, not only as a matter of the medical health of the individuals who comprise the United States, but also as a matter of national financial health. The Coalition sponsors a web site http://www.stemcellaction.org and can be found on Twitter @StemCellAction and on Facebook at http://www.facebook.com/stemcellaction.

SOURCE The Stem Cell Action Coalition

-0-

More here:
Stem Cell Action Coalition Opposes Virginia Personhood Bill

LSVT® LOUD Treatment Benefits Parkinson's Disease Patient — Hendricks Regional Health – Video

31-10-2011 14:20 Nearly 90 percent of patients with Parkinson's Disease (PD) have speech problems that start early in the disease process and progressively worsen. These speech problems can make it difficult for patients to be heard or understood by others, affecting their quality of life. Hendricks Regional Health offers LSVT®LOUD, an innovative treatment protocol that has been proven to improve voice and speech in individuals with PD. The program, offered by our speech therapy team, is recommended for virtually any patient with PD. Patient Ed Burns recently had great success improving his communication skills throughout the course of treatment. Burns works as a call-center representative, so his voice is his livelihood. Hear how this program has made a great difference in his life.

Originally posted here:
LSVT® LOUD Treatment Benefits Parkinson's Disease Patient -- Hendricks Regional Health - Video

LSVT® LOUD Treatment Benefits Parkinson’s Disease Patient — Hendricks Regional Health – Video

31-10-2011 14:20 Nearly 90 percent of patients with Parkinson's Disease (PD) have speech problems that start early in the disease process and progressively worsen. These speech problems can make it difficult for patients to be heard or understood by others, affecting their quality of life. Hendricks Regional Health offers LSVT®LOUD, an innovative treatment protocol that has been proven to improve voice and speech in individuals with PD. The program, offered by our speech therapy team, is recommended for virtually any patient with PD. Patient Ed Burns recently had great success improving his communication skills throughout the course of treatment. Burns works as a call-center representative, so his voice is his livelihood. Hear how this program has made a great difference in his life.

Originally posted here:
LSVT® LOUD Treatment Benefits Parkinson's Disease Patient -- Hendricks Regional Health - Video

Zumba for Parkinson's Disease patients – Video

22-12-2011 14:04 In the spring and fall of 2011, BIDMC brought a modified form of the fitness craze ZUMBA to Parkinson's patients and their family members. Co-developer of the Zumba Gold Program, Josie Gardiner, inspired participants to step and sway to a driving Latin beat. The results were, well, moving! The Parkinson's Disease and Movement Disorders Center will be running a winter Zumba Gold class beginning in January 2012. Visit bidmc.org/pdcenter to learn more.

Read the original here:
Zumba for Parkinson's Disease patients - Video

Zumba for Parkinson’s Disease patients – Video

22-12-2011 14:04 In the spring and fall of 2011, BIDMC brought a modified form of the fitness craze ZUMBA to Parkinson's patients and their family members. Co-developer of the Zumba Gold Program, Josie Gardiner, inspired participants to step and sway to a driving Latin beat. The results were, well, moving! The Parkinson's Disease and Movement Disorders Center will be running a winter Zumba Gold class beginning in January 2012. Visit bidmc.org/pdcenter to learn more.

Read the original here:
Zumba for Parkinson's Disease patients - Video